These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32735623)

  • 1. Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry.
    Cotes Sanchís A; Gallego J; Hernandez R; Arrazubi V; Custodio A; Cano JM; Aguado G; Macias I; Lopez C; López F; Visa L; Garrido M; Martínez Lago N; Fernández Montes A; Limón ML; Azkárate A; Pimentel P; Reguera P; Ramchandani A; Cacho JD; Martín Carnicero A; Granja M; Martín Richard M; Hernández Pérez C; Hurtado A; Serra O; Buxo E; Vidal Tocino R; Jimenez-Fonseca P; Carmona-Bayonas A
    PLoS One; 2020; 15(7):e0235848. PubMed ID: 32735623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.
    Valcarcel S; Gallego J; Jimenez-Fonseca P; Diez M; de Castro EM; Hernandez R; Arrazubi V; Custodio A; Cano JM; Montes AF; Macias I; Visa L; Calvo A; Tocino RV; Lago NM; Limón ML; Granja M; Gil M; Pimentel P; Macia-Rivas L; Pérez CH; Mangas M; Carnicero AM; Cerdà P; Gonzalez LG; Navalon FG; Rambla MDM; Richard MM; Carmona-Bayonas A
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):4077-4089. PubMed ID: 36042046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
    Yoshikawa T; Muro K; Shitara K; Oh DY; Kang YK; Chung HC; Kudo T; Chin K; Kadowaki S; Hamamoto Y; Hironaka S; Yoshida K; Yen CJ; Omuro Y; Bai LY; Maeda K; Ozeki A; Yoshikawa R; Kitagawa Y
    JAMA Netw Open; 2019 Aug; 2(8):e198243. PubMed ID: 31373648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
    Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
    BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
    Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
    Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry.
    Viúdez A; Carmona-Bayonas A; Gallego J; Lacalle A; Hernández R; Cano JM; Macías I; Custodio A; Martínez de Castro E; Sánchez A; Iglesia L; Reguera P; Visa L; Azkarate A; Sánchez-Cánovas M; Mangas M; Limón ML; Martínez-Torrón A; Asensio E; Ramchandani A; Martín-Carnicero A; Hurtado A; Cerdà P; Garrido M; Sánchez-Bayonas R; Serrano R; Jiménez-Fonseca P;
    Clin Transl Oncol; 2020 May; 22(5):734-750. PubMed ID: 31385226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
    Kang YK; Ryu MH; Park SH; Kim JG; Kim JW; Cho SH; Park YI; Park SR; Rha SY; Kang MJ; Cho JY; Kang SY; Roh SY; Ryoo BY; Nam BH; Jo YW; Yoon KE; Oh SC
    Ann Oncol; 2018 May; 29(5):1220-1226. PubMed ID: 29438463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer.
    Izawa N; Sunakawa Y; Doi A; Arai H; Horie Y; Hirakawa M; Mizukami T; Ogura T; Tsuda T; Nakajima TE
    Oncology; 2019; 97(2):94-101. PubMed ID: 31195391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.
    Horita Y; Nishino M; Sugimoto S; Kida A; Mizukami A; Yano M; Arihara F; Matsuda K; Matsuda M; Sakai A
    Anticancer Drugs; 2019 Jan; 30(1):98-104. PubMed ID: 30124494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
    Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
    Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
    Parisi A; Cortellini A; Roberto M; Venditti O; Santini D; Dell'Aquila E; Stellato M; Marchetti P; Occhipinti MA; Zoratto F; Mazzuca F; Tinari N; De Tursi M; Iezzi L; Natoli C; Ratti M; Pizzo C; Ghidini M; Porzio G; Ficorella C; Cannita K
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2365-2373. PubMed ID: 31280347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
    Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention of platinum sensitivity till late stages of tumour progression may imply improved prognosis of oesophageal and gastric cancers.
    Hingorani M; Dixit S; Roy R; Maraveyas A
    Oncol Res Treat; 2015; 38(1-2):28-34. PubMed ID: 25634795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy.
    Shitara K; Matsuo K; Muro K; Doi T; Ohtsu A
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1383-9. PubMed ID: 23708301
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer.
    Jeon Y; Lim SH; Lee J; Kang WK; Jang JY; Jeong SY; Choi D; Kim ST
    J Gastrointest Oncol; 2023 Dec; 14(6):2346-2353. PubMed ID: 38196521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.
    Kubota Y; Kawazoe A; Sasaki A; Mishima S; Sawada K; Nakamura Y; Kotani D; Kuboki Y; Taniguchi H; Kojima T; Doi T; Yoshino T; Ishii G; Kuwata T; Shitara K
    Clin Cancer Res; 2020 Jul; 26(14):3784-3790. PubMed ID: 32156744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
    Yamaguchi K; Fujitani K; Nagashima F; Omuro Y; Machida N; Nishina T; Koue T; Tsujimoto M; Maeda K; Satoh T
    Gastric Cancer; 2018 Nov; 21(6):1041-1049. PubMed ID: 29508095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
    Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.